Human infection challenge in the pandemic era and beyond, HIC-Vac annual meeting report, 2022
Author(s)
Type
Journal Article
Abstract
HIC-Vac is an international network of researchers dedicated to developing human infection challenge studies to accelerate vaccine development against pathogens of high global impact. The HIC-Vac Annual Meeting (3rd and 4th November 2022) brought together stakeholders including researchers, ethicists, volunteers, policymakers, industry partners, and funders with a strong representation from low- and middle-income countries. The network enables sharing of research findings, especially in endemic regions. Discussions included pandemic preparedness and the role of human challenge to accelerate vaccine development during outbreak, with industry speakers emphasising the great utility of human challenge in vaccine development. Public consent, engagement, and participation in human challenge studies were addressed, along with the role of embedded social science and empirical studies to uncover social, ethical, and regulatory issues around human infection challenge studies. Study volunteers shared their experiences and motivations for participating in studies. This report summarises completed and ongoing human challenge studies across a variety of pathogens and demographics, and addresses other key issues discussed at the meeting.
Date Issued
2023
Date Acceptance
2023-10-30
Citation
Immunotherapy Advances, 2023, 3 (1)
ISSN
2732-4303
Publisher
Oxford University Press
Journal / Book Title
Immunotherapy Advances
Volume
3
Issue
1
Copyright Statement
© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Immunology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/38020312
Subjects
controlled human infection models
experimental medicine
infectious disease
low-middle-income countries
mucosal immunology
vaccination
Publication Status
Published
Coverage Spatial
England
Article Number
ltad024
Date Publish Online
2023-10-31